Biosimilar Herzuma launching in Europe for the treatment of breast cancer

The Mundipharma global network of independent associated companies today announced that Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months.

Herzuma, which is a biosimilar of blockbuster cancer drug Herceptin from Swiss pharma giant Roche (ROG: SIX), was granted European Union marketing authorization on February 9 this year, for the treatment of patients with early breast cancer, metastatic breast cancer or metastatic gastric cancer whose tumours have either HER2 overexpression or HER2 gene amplification.

In March this year, South Korean firm Celltrion Healthcare (Kosdaq: 068270) granted exclusive distribution rights to its trastuzumab biosimilar, Herzuma, in seven European Union markets including Germany, Italy and the UK, to the Mundipharma l network.